Checkpoint Therapeutics, Inc. (CKPT)
4.260
0.00 (0.00%)
Inactive · Last trade price on May 29, 2025
Checkpoint Therapeutics Revenue
Checkpoint Therapeutics had revenue of $41.00K in the twelve months ending March 31, 2025, down -39.71% year-over-year. In the year 2024, Checkpoint Therapeutics had annual revenue of $41.00K, down -60.19%.
Revenue (ttm)
$41.00K
Revenue Growth
-39.71%
P/S Ratio
8,703.26
Revenue / Employee
$1,708
Employees
24
Market Cap
356.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 41.00K | -62.00K | -60.19% |
| Dec 31, 2023 | 103.00K | -89.00K | -46.35% |
| Dec 31, 2022 | 192.00K | -76.00K | -28.36% |
| Dec 31, 2021 | 268.00K | -801.00K | -74.93% |
| Dec 31, 2020 | 1.07M | -639.00K | -37.41% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCKPT News
- 6 months ago - Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates - GlobeNewsWire
- 6 months ago - CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT - Business Wire
- 7 months ago - Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire
- 8 months ago - Sun Pharma to Acquire Checkpoint Therapeutics - PRNewsWire
- 11 months ago - Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval - Seeking Alpha
- 11 months ago - Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewsWire
- 1 year ago - Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date - Seeking Alpha
- 1 year ago - Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - GlobeNewsWire